Report: Most States Fail with Healthcare Price, Quality Transparency

Feb. 12, 2018
Most states fail to provide consumers with the information they need to make informed healthcare choices and even fewer provide data on the price and quality of care together, according to a new report.

Most states fail to provide consumers with the information they need to make informed healthcare choices and even fewer provide data on the price and quality of care together, according to a new report.

The report, from independent organizations Altarum and Catalyst for Payment Reform (CPR), concluded that in 49 out of 50 states, consumers are basically in the dark when it comes to making value-based healthcare decisions according to a new report on health care price and physician quality transparency.

For the past four years Altarum (previously the Health Care Incentives Improvement Institute) and CPR published their joint price transparency and physician quality report cards at separate times during the year. This year, to reflect the growing importance of providing price and quality information in tandem, the organizations have combined the report cards into a single report.

“We continue to find that most states miss the mark in providing consumers with usable price and quality information,” François de Brantes, vice president and director of Altarum’s Center for Value in Health Care, said in a statement. “Only one state—Maine—scored above an F in both price and quality information. That means that in 49 out of 50 states, consumers are basically in the dark when it comes to making value- based health care decisions. But it also means that providing good information to consumers is possible and all states can get there. They need to have the will to do it.”

Drilling down, this year 43 states received an F for failing to meet even minimum price transparency standards. States that did make the grade are those with robust laws promoting and mandating price transparency that offer consumer-friendly, free websites with meaningful price, the report revealed. For price transparency, the states with passing grades were: Maine (A); New Hampshire (A); Maryland (B); Oregon (B); Colorado (C); Vermont (C); and Virginia (C).

Meanwhile, on the quality transparency front, 42 states received an F and no states improved in score from last year highlighting the need for significant progress to be made. States that scored well have independent, free websites for consumers with current data on a high percentage of physicians in the state. These websites contain quality measures that are meaningful to consumers and offer access to easily interpretable information, according to the report.

States with passing grades on quality transparency included: California (A); Minnesota (A); Maine (C); and Michigan (C).

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1